Weekly Recap: 81.8% ORR in Phase 1b and $250M TCGX-led ADS placement

What happened

Zai Lab reported Phase 1b results for zoci plus atezolizumab, showing an 81.8% confirmed ORR, 81.9% six-month PFS, low grade ≥3 side effects and no DLTs. A Phase 3 trial is planned for end-2026. Zai Lab also announced a $250 million ADS private placement led by TCGX, expected to close October 27, 2026.

Confirmed

Global impact / market context

The $250 million placement gives Zai Lab cash to fund pipeline development and general operations without waiting on future revenue. That matters because drug trials are costly and take years. If the Phase 3 trial succeeds, the company could gain a larger commercial opportunity, but failure would consume cash with little return.

Analyst inference

Biotech companies often raise money after promising early trial data, because results can attract specialist investors like TCGX. Investors will weigh the strong response rate against the cost of later-stage trials. The private placement of ADSs, which are shares traded on a US exchange, may also affect how existing holders view dilution.

Analyst inference

What to watch

1. Zai Lab said the $250 million ADS private placement is expected to close on October 27, 2026, which means investors should watch whether the deal actually completes as announced. Confirmed
2. Zai Lab plans a Phase 3 trial for zoci plus atezolizumab for end-2026, so watch for trial design details, enrollment timing and whether the plan stays on schedule. Proposed
3. Because proceeds are designated for pipeline development and general corporate purposes, watch future spending updates to see whether cash is used on trials or elsewhere. Analyst inference

Evidence

• Original source link unavailable